By: Kyung Hee Choi, Vice President of Asian Health Services, Holy Name Medical Center, Teaneck, New Jersey
In a study of 11,177 Asian Americans screened for hepatitis B, Holy Name Medical Center found a 3.2% prevalence rate; linkage to care is an ongoing challenge.
By: Katie Burk, MPH; Viral Hepatitis Coordinator; San Francisco Department of Public Health and Colleen Lynch, MD, MPH; Medical Director of Care Coordination; San Francisco Department of Public Health
San Francisco Department of Public Health’s innovative primary care-based HCV treatment program expands HCV treatment access to vulnerable populations.
By: Corinna Dan, RN, MPH, Viral Hepatitis Policy Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services
HRSA’s HIV/AIDS Bureau has awarded a new initiative to improve hepatitis C virus (HCV) services among HIV/HCV coinfected people of color, funded under the FY 2016 Secretary’s Minority AIDS Initiative Fund.
By: Dr. Sean T. Allen, Senior Policy Advisor, Office of National Drug Control Policy, Executive Office of the President
Dr. Sean Allen, White House Office of National Drug Control Policy, describes strategies for preventing the spread of infectious diseases due to substance use
By: Corinna Dan, RN, MPH, Viral Hepatitis Policy Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services
The Federal Bureau of Prisons has released an October 2016 update to their guidance document, Evaluation and Management of Chronic Hepatitis C Virus Infection.
By: National Alliance of State and Territorial AIDS Directors
According to the latest CDC Vital Signs, only 1 in 4 people who inject drugs (PWID) in 22 US cities reported getting all their needles from sterile sources.
By: Richard Wolitski, Ph.D., Director, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services and Corinna Dan, RN, MPH, Viral Hepatitis Policy Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services
December 1st is World AIDS Day, and provides an opportunity to discuss the unique issues related to HIV and viral hepatitis coinfection, as well as strategies for moving forward.
By: Jane Pan, Executive Director, Hepatitis B Initiative of Washington, D.C. (HBI-DC)
Jane Pan, Executive Director of Hepatitis B Initiative of Washington, D.C. (HBI-DC), and a 2016 White House Hepatitis Testing Day Awardee, describes HBI-DC’s 10 years of community-based direct services.
By: Corinna Dan, RN, MPH, Viral Hepatitis Policy Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services
On November 10, 2016, the U.S. Food and Drug Administration (FDA) approved Vemlidy® (tenofovir alafenamide), a once-daily oral treatment for chronic hepatitis B infection in adults.
